Month: December 2022

El-Assal, Mona Ibrahim published the artcileNano-sponge novel drug delivery system as carrier of anti-hypertensive drug, Computed Properties of 89076-64-2, the publication is International Journal of Pharmacy and Pharmaceutical Sciences (2019), 11(10), 47-63, database is CAplus.

The study was designed to prepare Nano-sponge formulation loaded with nifedipine. Studying parameters which affecting the formulas in addition to pharmacokinetics and toxicity tests. Nine Nano-sponge formulations were prepared by the solvent evaporation technique. Different ratios of polymer ethylcellulose, COpolymers β-cyclodextrin and hydroxypropyl β-cyclodextrin in addition to solubilizing agent polyvinyl alc. were used. Thermal anal., X-ray powder diffraction (XRPD), shape and surface morphol., particle size, %production yield, %porosity, % swelling, and % drug entrapment efficiency of Nano-sponge were examined Release kinetic also studied beside comparison of pharmacokinetic parameters of the optimum choice formula and marketed one in addition to Toxicol. consideration. Particle size in the range of 119.1 nm to 529 nm which were increased due to the increase in the concentration of polymer to the drug. Nano-sponge revealed porous, spherical nature. Increased in the drug/polymer molar ratios (1:1 to 1:3) may increase their % production yield ranged from 62.1% to 92.4%. The drug content of different formulations was in the range of 77.9% to 94.7%, and entrapment efficiency was in the range of 82.72 % to 96.63%. Drug released in controlled sustained pattern and followed Higuchi, s diffusion mechanism. Pharmacokinetic parameters of optimized formula showed significant higher maximum plasma drug concentration, area under plasma concentration-time curve, volume of distribution and mean residence time. Nano-sponge loaded drug proved biol. safety at low concentrations Nano-sponge drug delivery system has showed small Nano size, porous with controlled drug release and significant-high plasma drug concentration that improved solubility, drug bioavailability and proved safety.

International Journal of Pharmacy and Pharmaceutical Sciences published new progress about 89076-64-2. 89076-64-2 belongs to pyridine-derivatives, auxiliary class Pyridine,Nitro Compound,Benzene, name is 5-Nitro-2-phenylpyridine, and the molecular formula is C11H8N2O2, Computed Properties of 89076-64-2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

El Ali, Bassam published the artcileRh₆(CO)₁₆-H₃PW₁₂O₄₀-catalyzed one pot hydroformylation-cyclotrimerization of cyclohexene and cyclopentene to 2,4,6-trisubstituted 1,3,5-trioxanes, Recommanded Product: Pyridine-3-sulfonic acid, the publication is Journal of Molecular Catalysis A: Chemical (2003), 203(1-2), 53-58, database is CAplus.

One-pot hydroformylation-cyclotrimerization of cyclopentene and cyclohexene was selectively catalyzed by Rh₆(CO)₁₆ and H₃PW₁₂O₄₀·xH₂O (HPA-W₁₂) in THF at 40 atm (CO/H₂ = 1/1) and afforded 2,4,6-tris(cycloalkyl)-1,3,5-trioxanes as major products along with the corresponding aldehydes.

Journal of Molecular Catalysis A: Chemical published new progress about 636-73-7. 636-73-7 belongs to pyridine-derivatives, auxiliary class Pyridine,Sulfonic acid, name is Pyridine-3-sulfonic acid, and the molecular formula is C5H5NO3S, Recommanded Product: Pyridine-3-sulfonic acid.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Christophe, Bernard published the artcileOccurrence of early after depolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, the publication is Toxicology and Applied Pharmacology (2022), 115914, database is CAplus and MEDLINE.

The goal of the CiPA initiative (Comprehensive in vitro Proarrhythmia Assay) was to assess a more accurate prediction of new drug candidate proarrhythmic severe liabilities such as torsades de pointes, for example. This new CiPA paradigm was partly based on in silico reconstruction of human ventricular cardiomyocyte action potential useful to identify repolarization abnormalities such early afterdepolarization (EAD), for example. Using the ToR-ORd algorithm (Tomek-Rodriguez-O’Hara-Rudy dynamic model), the aim of the present work was (i) to identify intracellular parameters leading to EAD occurrence under healthy and hypertrophic cardiomyopathy (HCM) conditions and (ii) to evaluate the prediction accuracy of compound torsadogenic risk based on EAD occurrence using a large set of 109 torsadogenic and non-torsadogenic compounds under both exptl. conditions. In silico results highlighted the crucial involvement of Ca++ handling in the ventricular cardiomyocyte intracellular subspace compartment for the initiation of EAD, demonstrated by a higher amplitude of Ca++ release from junctional sarcoplasmic reticulum to subspace compartments (Jrel) measured at EAD take-off voltage in the presence vs. the absence of EAD initiated either by high IKr inhibition or by high enough concentration of a torsadogenic compound under both exptl. conditions. Under healthy or HCM conditions, the prediction accuracy of the torsadogenic risk of compound based on EAD occurrence was observed to be 61 or 92%, resp. This high accuracy under HCM conditions was discussed regarding its usefulness for cardiac safety pharmacol. at least at early drug screening/preclin. stage of the drug development process.

Toxicology and Applied Pharmacology published new progress about 21829-25-4. 21829-25-4 belongs to pyridine-derivatives, auxiliary class Membrane Transporter/Ion Channel,Calcium Channel, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Recommanded Product: Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Chiswell, B. published the artcilePlatinum complexes of some deprotonatable tridentate ligands, Related Products of pyridine-derivatives, the publication is Australian Journal of Chemistry (1968), 21(8), 1997-2001, database is CAplus.

Pt(II) and Pt(IV) complexes of 1,3-bis(2-pyridyl)-1,2-diazaprop-2-ene and ligands of similar structure, but with Me “blocking groups” adjacent to the pyridine N atoms, were studied. In neutral solution, these ligands lose a proton upon interaction with either Pt(II) or Pt(IV) salts to yield highly colored complexes soluble in organic solvents. Protonated compounds of both oxidation states can be obtained, but such compounds are unstable in neutral solution and readily yield deprotonated complexes.

Australian Journal of Chemistry published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, Related Products of pyridine-derivatives.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Chen, Hong-hua published the artcileEfficacy of manual reduction combined with betahistine mesylate in treatment of benign paroxysmal positional vertigo, SDS of cas: 54856-23-4, the publication is Xiandai Zhenduan Yu Zhiliao (2017), 28(7), 1235-1236, database is CAplus.

To explore the efficacy of manual reduction combined with drugs in the treatment of 60 cases of benign paroxysmal positional vertigo. Patients who were diagnosed with benign paroxysmal positional vertigo in our hospital from Feb. 2013 to Jan. 2015 were collected and randomly divided into a study group and a control group. The basic treatment of the two groups was manual reduction, and the study group was treated with betahistine mesylate tablets. The therapeutic effects of the two groups were compared for benign paroxysmal positional vertigo. The two groups were scored by the Vertigo Disorder Rating Scale before and after treatment. The therapeutic effects of the study group and the control group for benign paroxysmal positional vertigo were 100% and 66.7%, resp., and there was a difference (P < 0.05). The study group and the control group had no difference in the scores of the Vertigo Disorder Rating Scale before treatment (P > 0.05). There was a difference in the scores of the vertigo disorder rating scale between the study group and the control group after treatment (P < 0.05). This article believes that manual reduction combined with drugs has a definite effect in the treatment of benign paroxysmal positional vertigo and can significantly improve the symptoms of patients.

Xiandai Zhenduan Yu Zhiliao published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C10H20N2O6S2, SDS of cas: 54856-23-4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Asahara, Haruyasu published the artcileSubstituent Diversity-directed Synthesis of Nitropyridines and Nitroanilines by Three-component Ring Transformation, Quality Control of 89076-64-2, the publication is Procedia Engineering (2017), 1046-1057, database is CAplus.

A novel method for synthesis of various kinds of nitroarenes by using a three-component ring transformation (TCRT) of dinitropyridone with ketones in the presence of ammonium acetate as nitrogen source is developed. This method requires only simple manipulations and mild reaction conditions. Furthermore, the modification of obtained nitropyridine or nitroaniline frameworks can be easily obtained only changing a com. available substrates.

Procedia Engineering published new progress about 89076-64-2. 89076-64-2 belongs to pyridine-derivatives, auxiliary class Pyridine,Nitro Compound,Benzene, name is 5-Nitro-2-phenylpyridine, and the molecular formula is C11H8N2O2, Quality Control of 89076-64-2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Anonymous published the artcilePreparation of new nitrogen-bridged heterocycles. 72. A new approach to 1-acyl-3-(substituted methylthio)thieno[3′,4′:4,5]imidazo[1,5-a]pyridine derivatives [Erratum to document cited in CA154:284193], Application In Synthesis of 17281-59-3, the publication is Chemical & Pharmaceutical Bulletin (2010), 58(12), 1672, database is CAplus.

On page 1502 the title contains an error; the correct title is given. On page 1509 in the right column, lines 3,8 and 7 and in the left column, lines 8 and 7, imidazo[1,5-α]pyridine is incorrect; the correction is given. On page 1510 in the left column, lines 3 and 17, imidazo[1,5-α]pyridine is incorrect; the correction is given. On page 1510, a reference should be added; the reference is given.

Chemical & Pharmaceutical Bulletin published new progress about 17281-59-3. 17281-59-3 belongs to pyridine-derivatives, auxiliary class Pyridine,Nitrile,Salt, name is 1-(Cyanomethyl)pyridin-1-ium chloride, and the molecular formula is C7H7ClN2, Application In Synthesis of 17281-59-3.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Anderegg, Giorgio published the artcilePyridine derivatives as complexing agents. IX. Stability constants of complexes with 2-aminomethylpyridine, 6-methyl-2-aminomethylpyridine, 2-pyridylhydrazine, 2,2′-dipyridylamine, and 1-(α-pyridylmethylene)-2-(α’-pyridyl)hydrazine, COA of Formula: C11H10N4, the publication is Helvetica Chimica Acta (1971), 54(2), 509-12, database is CAplus.

The stability constants for the Mn(II), Co(II), Ni(II), Cu(II), Zn(II), Hg(II), Cd(II), and Ag(I) complexes of 2-aminomethylpyridine, 6-methyl-2-aminomethylpyridine, 2-pyridylhydrazine, 2,2′-dipyridylamine, 1-(2-pyridylmethylene)-2-(2′-pyridyl)hydrazine are reported. In all cases logK1 > logK2.

Helvetica Chimica Acta published new progress about 2215-33-0. 2215-33-0 belongs to pyridine-derivatives, auxiliary class Pyridine,Amine, name is 2-((2-(Pyridin-2-yl)hydrazono)methyl)pyridine, and the molecular formula is C11H10N4, COA of Formula: C11H10N4.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Almutairi, Zainab M. published the artcileComparative genomics of HORMA domain-containing proteins in prokaryotes and eukaryotes, Application of 3,5-Diethyl-1-phenyl-2-propyl-1,2-dihydropyridine, the publication is Cell Cycle (2018), 17(23), 2531-2546, database is CAplus and MEDLINE.

In eukaryotes, critical regulation of cell cycle is required to ensure the integrity of cell division. HORMA-containing proteins include various proteins that contain HORMA domain and play important role in the regulation of cell cycle in eukaryotes. Many types of HORMA-containing proteins are found in eukaryotes, but their role in prokaryotes has not been proven. Therefore, we conduct an extensive search in GenBank for HORMA-containing proteins in prokaryotes to compare HORMA domain structure and architecture across eukaryotes and prokaryotes. Strikingly, genome sequencing for many prokaryotic organisms reveals that HORMA domain is present in many bacterial genomes and only two archaeal genomes. We perform sequence alignment and phylogenetic anal. to trace the evolutionary link between HORMA domain in prokaryotes and eukaryotes. HORMA domain in prokaryotes appears to vary in sequence and architecture. Interestingly, seven bacterial HORMA-containing proteins and the two archaeal HORMA-containing proteins showed close relationships with eukaryotic HORMA-containing proteins. Addnl., we uncovered remarkable close relationships between HORMA-containing protein from Chlamydia trachomatis and eukaryotic MAD2 proteins. Our results provide insights into evolutionary relationships between prokaryotic and eukaryotic systems, which facilitate our understanding of the evolution of cell cycle regulation mechanisms.

Cell Cycle published new progress about 34562-31-7. 34562-31-7 belongs to pyridine-derivatives, auxiliary class Pyridine,Benzene, name is 3,5-Diethyl-1-phenyl-2-propyl-1,2-dihydropyridine, and the molecular formula is C18H25N, Application of 3,5-Diethyl-1-phenyl-2-propyl-1,2-dihydropyridine.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem

Li, Xing published the artcileNewly-generated Al(OH)₃-supported Pd nanoparticles-catalyzed Stille and Kumada coupling reactions of diazonium salts, (Het)aryl chlorides, Quality Control of 89076-64-2, the publication is Tetrahedron (2016), 72(1), 69-75, database is CAplus.

A ligand-free Pd/Al(OH)₃ nano-catalyst which is prepared by one-pot three-component method using Pd(PPh₃)₄, tetra (ethylene glycol), and aluminum tri-sec-butoxide exhibits excellent catalytic activity in Stille cross-couplings of (Het)aryl chlorides, arenediazonium tetrafluoroborate salts with phenyltributylstannane, resp., and Kumada couplings of (Het)aryl chlorides with various Grignard reagents. More importantly, these two processes show excellent functional group compatibility with moderate to good yields and they are also versatile with respect to not only (Het)aryl chlorides, but also diazonium salts, and heteroaryl Grignard reagents. The nano-catalyst could also be recycled and reused 5 times without loss of activity and decrease of yield.

Tetrahedron published new progress about 89076-64-2. 89076-64-2 belongs to pyridine-derivatives, auxiliary class Pyridine,Nitro Compound,Benzene, name is 5-Nitro-2-phenylpyridine, and the molecular formula is C11H8N2O2, Quality Control of 89076-64-2.

Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem